Kava (Piper methysticum), a plant native to the South Pacific, has been traditionally used for its calming effects. In Western contexts, standardized extracts are sometimes explored as a complementary option for managing symptoms of anxiety. At our psychiatric practice, we prioritize evidence-based approaches and emphasize that kava is not a first-line treatment or substitute for proven therapies like psychotherapy or FDA-approved medications.
Evidence for Anxiety
Multiple systematic reviews and meta-analyses of randomized controlled trials (RCTs) suggest that kava extract can provide modest short-term relief for anxiety symptoms compared to placebo. A 2000 Cochrane review and meta-analysis of seven trials found a significant reduction in Hamilton Anxiety Scale (HAM-A) scores favoring kava (weighted mean difference around 3.9–9.7 points).
More recent analyses (e.g., 2018) indicate kava was more effective than placebo in some trials, with a responder risk ratio of 1.50, though results are mixed across studies. Effects appear most relevant for generalized anxiety disorder (GAD) in short-term use (typically 4–8 weeks). Benefits may be comparable to some conventional anxiolytics like buspirone in certain trials, without significant cognitive impairment.
However, not all studies show consistent superiority over placebo, particularly in larger or longer-term GAD trials. Evidence quality varies due to differences in extracts, dosages, and patient populations.
Evidence for Depression
Evidence for kava in depression is more limited. The Kava Anxiety Depression Spectrum Study (KADSS) using an aqueous extract (250 mg kavalactones/day) showed reductions in both anxiety and depressive symptoms (e.g., Montgomery-Asberg Depression Rating Scale) in participants with comorbid symptoms. Some reviews note potential mood benefits tied to anxiety reduction, but kava is not established as a primary antidepressant treatment. More robust research is needed.
Recommended Dosing
Standardized extracts are typically dosed at **60–280 mg of kavalactones per day**, often divided into 2–3 doses, for short-term use (up to 4–8 weeks, sometimes up to 24 weeks under supervision). A common maximum suggested to minimize risk is around 250 mg kavalactones daily.
Use only high-quality, root-derived products from reputable sources (preferably noble cultivars and aqueous or standardized extracts like WS 1490). Avoid exceeding recommended doses or long-term use without medical oversight. Always consult a healthcare provider before starting, especially if combining with other treatments.
Side Effects and Risks
Common side effects include mild nausea, stomach upset, headache, drowsiness, or dizziness. These are generally comparable to placebo in short-term studies.
The primary concern is hepatotoxicity (liver injury). Rare but serious cases of hepatitis, liver failure, and even transplants or death have been reported, leading to FDA consumer advisories in 2002. Risks may increase with higher doses, prolonged use, poor-quality extracts (e.g., using leaves/stems instead of roots), alcohol, or concurrent hepatotoxic medications. Liver function monitoring is advisable if used.
Other potential risks include skin changes (with heavy traditional use), interactions with CNS depressants or medications metabolized by the liver, and contraindications in pregnancy, breastfeeding, or liver disease. Kava is not recommended for children.
Important Disclaimer: This information is for educational purposes only and does not constitute medical advice. Kava should only be considered under the guidance of a qualified healthcare professional as part of a comprehensive treatment plan. Individual responses vary, and potential benefits must be weighed against risks. Discuss your symptoms and options with your psychiatrist for personalized care.
References
– Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003.
– Smith K, et al. Systematic review of Kava Kava for anxiety symptoms. 2018.
– Sarris J, et al. Kava Anxiety Depression Spectrum Study (KADSS). 2009.
– NCBI LiverTox: Kava Kava. Updated information on hepatotoxicity.
– FDA Consumer Advisory and related safety reviews.
– Additional reviews from Examine.com, PubMed, and systematic analyses on efficacy and safety.